Protagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Protagonist Therapeutics (PTGX) shares slumped 53% by Tuesday afternoon, a day after the biopharmaceutical company said a phase 2 study of its proposed...
Protagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative...
| Address | 7707 Gateway Boulevard Newark, California 94560-1160 |
| Phone | +1.510.474.0170 |
| Number of Employees | 64 |
| Recent SEC Filing | 08/05/2022 S-3 |
| President, Chief Executive Officer & Director | Dinesh V. Patel |
| Chief Financial Officer & Executive Vice President | Asif Ali |
| Vice President-Technology | Mark L. Smythe |
| Chief Research & Development Strategy Officer | David Y. Liu |
| Price Open | $10.56 |
| Previous Close | $10.40 |
| 52 Week Range | $6.91 - 50.54 |
| Market Capitalization | $559.6 M |
| Shares Outstanding | 49.1 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.74 |
| Beta vs. S&P 500 | N/A |
| Revenue | $30.9 M |
| Net Profit Margin | -291.70% |
| Return on Equity | -44.25% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
